"Drug and medical device highlights 2018: Helping you maintain and improve your health"
Hold the syringe or pen vertically as if pointing at the sky, ensuring the needle travels straight downward into the fatty subcutaneous layer
Key monitoring strategies used in these trials include: Regular laboratory assessments (liver enzymes, lipase and amylase, renal function markers, HbA1c and glucose) Renal function monitoring, particularly if significant gastrointestinal adverse effects occur and dehydration is a concern Cardiovascular monitoring, including resting heart rate and blood pressure GLP-1 and glucagon receptor agonism can increase resting heart rate, which requires careful evaluation in those with pre-existing cardiac conditions Calcitonin measurement and thyroid ultrasound where specified by trial protocol, to monitor for any signal related to thyroid C-cell changes (noting that routine thyroid function tests are not the specific safety assessment for this risk) Body composition assessments using imaging tools, which are research-protocol-specific rather than routine clinical monitoring, to evaluate changes in lean muscle mass versus fat mass Patient-reported outcome measures to capture quality-of-life changes and symptom burden over time Ophthalmic assessments in participants with pre-existing diabetic retinopathy, given the potential for early worsening with rapid glycaemic improvement The glucagon receptor component of retatrutide introduces additional monitoring considerations
We realized, however, that additional requirements would be needed to achieve that aim
For example, back pain and musculoskeletal discomfort appear in certain GLP-1 agonist SmPCs as uncommon or common adverse reactions
doi: 10.4269/ajtmh.20-0473 223 ProalA
.png&w=828&q=100)
.png)
